Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | HTT | P42858 | 6/20 | 0.74 |
| ▸ | CDK8 | P49336 | 3/20 | 0.74 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | STAT1 | P42224 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426655 | 0.85 | CDK8 (1.00) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL12562445 | 0.85 | ALDH1A1 (0.80) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL6100788 | 0.85 | ALDH1A1 (0.80) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL429541 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL8242756 | 0.84 | ALDH1A1 (0.74) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL16071457 | 0.84 | ALDH1A1 (0.72) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL8238314 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL8242825 | 0.81 | ALDH1A1 (0.62) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL17485804 | 0.80 | ALDH1A1 (1.00) | ALDH1A1KDM4EHTTCDK8CDK19 | |
| SCHEMBL4657890 | 0.75 | CDK8 (0.76) | ALDH1A1KDM4EHTTCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | ALDH1A1 1026/4885KDM4E 1129/4885HTT 374/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | ALDH1A1 1026/4885KDM4E 1129/4885HTT 374/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | ALDH1A1 1026/4885KDM4E 1129/4885HTT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.